+

WO1996017869A3 - Interleukin-6 (il-6) antagonists - Google Patents

Interleukin-6 (il-6) antagonists Download PDF

Info

Publication number
WO1996017869A3
WO1996017869A3 PCT/IT1995/000208 IT9500208W WO9617869A3 WO 1996017869 A3 WO1996017869 A3 WO 1996017869A3 IT 9500208 W IT9500208 W IT 9500208W WO 9617869 A3 WO9617869 A3 WO 9617869A3
Authority
WO
WIPO (PCT)
Prior art keywords
antagonists
shil
asn
abnormal
interleukin
Prior art date
Application number
PCT/IT1995/000208
Other languages
French (fr)
Other versions
WO1996017869A2 (en
Inventor
Gennaro Ciliberto
Carlo Toniatti
Original Assignee
Angeletti P Ist Richerche Bio
Gennaro Ciliberto
Carlo Toniatti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angeletti P Ist Richerche Bio, Gennaro Ciliberto, Carlo Toniatti filed Critical Angeletti P Ist Richerche Bio
Priority to EP95940401A priority Critical patent/EP0742794A1/en
Priority to AU41866/96A priority patent/AU4186696A/en
Priority to JP8517466A priority patent/JPH09503232A/en
Publication of WO1996017869A2 publication Critical patent/WO1996017869A2/en
Publication of WO1996017869A3 publication Critical patent/WO1996017869A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

These are antagonists of interleukin-6, characterised in that they consist of soluble forms of the receptor α of human IL-6 (shIL-6Rα) containing one or more mutation in the gp130 binding interface. In a preferred embodiment, the mutations are present in a position chosen from the group comprising Ala 228, Asn 230, His 280 and Asp 281. These antagonists can be used as agents capable of preventing and treating diseases caused by abnormal IL-6 activity. The figure shows the antagonist activity of the mutant Ala228Asp/Asn 230Asp/His280Ser/Asp281Val in comparison with the agonist properties of wild type shIL-6Rα. This antagonist can be used for preparation of drugs for the prevention, control and treatment of diseases caused by abnormal IL-6 bioactivity.
PCT/IT1995/000208 1994-12-06 1995-12-05 Interleukin-6 (il-6) antagonists WO1996017869A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP95940401A EP0742794A1 (en) 1994-12-06 1995-12-05 Interleukin-6 (il-6) antagonists
AU41866/96A AU4186696A (en) 1994-12-06 1995-12-05 Interleukin-6 (il-6) antagonists
JP8517466A JPH09503232A (en) 1994-12-06 1995-12-05 An IL-6 antagonist that is a soluble form of interleukin-6 (IL-6) receptor alpha mutated at the GP130 binding interface

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITRM940794A IT1274350B (en) 1994-12-06 1994-12-06 INTERLEUCHINA-6 (IL-6) ANTAGONISTS, WHICH CONSIST OF SOLUBLE FORMS OF THE ALFA RECEPTOR OF IL-6, CHANGED IN THE INTERFACE THAT LINKS TO GP 130
ITRM94A000794 1994-12-06

Publications (2)

Publication Number Publication Date
WO1996017869A2 WO1996017869A2 (en) 1996-06-13
WO1996017869A3 true WO1996017869A3 (en) 1996-08-29

Family

ID=11402851

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IT1995/000208 WO1996017869A2 (en) 1994-12-06 1995-12-05 Interleukin-6 (il-6) antagonists

Country Status (7)

Country Link
EP (1) EP0742794A1 (en)
JP (1) JPH09503232A (en)
CN (1) CN1139933A (en)
AU (1) AU4186696A (en)
CA (1) CA2177837A1 (en)
IT (1) IT1274350B (en)
WO (1) WO1996017869A2 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7091181B2 (en) 1994-12-12 2006-08-15 Omeros Corporation Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors
CA2230949C (en) * 1995-09-28 2009-11-17 Judith Chebath Synthetic peptides that inhibit il-6 activity
US6217858B1 (en) * 1997-02-11 2001-04-17 Hadasit & Medical Research Services & Development Company, Ltd. Pharmaceutical composition for treating hepatitis B virus (HBV) infection
GB9621095D0 (en) * 1996-10-09 1996-11-27 Imperial College Novel system
JPH10324639A (en) 1997-03-21 1998-12-08 Chugai Pharmaceut Co Ltd Preventing and therapeutic agent for disease associated with sensitized t cell containing il-6 antagonist as active ingredient
US7227837B1 (en) 1998-04-30 2007-06-05 At&T Labs, Inc. Fault tolerant virtual tandem switch
CA2237915A1 (en) 1998-05-19 1999-11-19 Stephen Shaughnessy Osteoporosis treatment
ATE350060T1 (en) 1998-08-24 2007-01-15 Chugai Pharmaceutical Co Ltd AGENTS FOR PREVENTING OR TREATING PANCREATITIS WHICH CONTAIN ANTI-IL-6 RECEPTOR ANTIBODIES AS THE ACTIVE COMPONENT
JP4799516B2 (en) * 1998-08-24 2011-10-26 中外製薬株式会社 A prophylactic or therapeutic agent for pancreatitis comprising an IL-6 antagonist as an active ingredient
AU1345000A (en) * 1998-11-05 2000-05-22 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain and inflammation
AU7078200A (en) 1999-08-27 2001-03-26 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Polypeptides, comprising il-6 ligand-binding receptor domains and related nucleic acids, antibodies, compositions, and methods of use
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
AUPR769501A0 (en) * 2001-09-14 2001-10-11 Biomolecular Research Institute Limited Cytokine receptor 1
CN100340294C (en) 2003-02-24 2007-10-03 中外制药株式会社 Therapeutic agent for spinal cord injury comprising interleukin 6 antagonist
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
BRPI0415505A (en) 2003-10-17 2006-12-12 Chugai Pharmaceutical Co Ltd mesothelioma therapeutic agent
AR048210A1 (en) 2003-12-19 2006-04-12 Chugai Pharmaceutical Co Ltd A PREVENTIVE AGENT FOR VASCULITIS.
AU2006300234B2 (en) 2005-10-14 2013-01-10 Chugai Seiyaku Kabushiki Kaisha Agents for suppressing damage to transplanted islets after islet transplantation
AR058135A1 (en) 2005-10-21 2008-01-23 Chugai Pharmaceutical Co Ltd AGENTS FOR THE TREATMENT OF CARDIOPATIAS
AR057582A1 (en) 2005-11-15 2007-12-05 Nat Hospital Organization AGENTS TO DELETE INDUCTION OF CYTOTOXIC T LYMPHOCYTES
US20090269335A1 (en) 2005-11-25 2009-10-29 Keio University Therapeutic agent for prostate cancer
ES2685915T3 (en) 2006-01-27 2018-10-15 Keio University Therapeutic agents for diseases involving choroidal neovascularization
WO2007116962A1 (en) 2006-04-07 2007-10-18 Osaka University Muscle regeneration promoter
RU2450829C2 (en) 2007-01-23 2012-05-20 Синсу Юниверсити Chronic rejection inhibitor
TW201503898A (en) 2008-06-05 2015-02-01 Chugai Pharmaceutical Co Ltd Neuroinvasion inhibitor
WO2011149046A1 (en) 2010-05-28 2011-12-01 独立行政法人国立がん研究センター Therapeutic agent for pancreatic cancer
SI2578231T1 (en) 2010-05-28 2023-01-31 Chugai Seiyaku Kabushiki Kaisha Antitumor t cell response enhancer
JP6442404B2 (en) 2013-06-11 2018-12-19 国立研究開発法人国立精神・神経医療研究センター Method for predicting treatment prognosis in patients with relapsing-remitting multiple sclerosis (RRMS), and method for determining new treatment indication
EP2898896A1 (en) 2014-01-22 2015-07-29 Université Pierre et Marie Curie (Paris 6) Agents for use in the treatment of retinal inflammation
EP4269440A3 (en) 2015-02-27 2024-02-28 Chugai Seiyaku Kabushiki Kaisha Composition for treating il-6-related diseases
EP3620531A4 (en) 2017-05-02 2021-03-17 National Center of Neurology and Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to il-6 and neutrophils
EP3747469A4 (en) 2018-01-31 2022-03-23 Motokazu Kato Therapeutic agent for asthma containing il-6 inhibitor
KR20210025054A (en) * 2018-06-21 2021-03-08 샤턱 랩스 인코포레이티드 Heterodimeric proteins and uses thereof
WO2020213665A1 (en) 2019-04-17 2020-10-22 国立大学法人広島大学 Therapeutic agent for urological cancer which is characterized by being administered with il-6 inhibitor and ccr2 inhibitor in combination
CN110133241B (en) * 2019-05-21 2022-05-27 中国食品药品检定研究院 Novel method for measuring biological activity of recombinant human soluble gp130-Fc fusion protein

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0591892A (en) * 1991-10-02 1993-04-16 Chuzo Kishimoto Il-6 receptor derivative

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0591892A (en) * 1991-10-02 1993-04-16 Chuzo Kishimoto Il-6 receptor derivative

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE STRAND TPSD *
DATABASE WPI Week 9320, Derwent World Patents Index; AN 93-161739, XP002003861 *
LIAUTARD ET AL.: "Epitope analysis of human IL-6 receptor gp80 molecule with monoclonal antibodies", EUR. CYTOKINE NETWORK, vol. 5, no. 3, May 1994 (1994-05-01) - June 1994 (1994-06-01), pages 293 - 300, XP000571448 *
SALVATI ET AL.: "Interleukin-6 (IL-6) antagonism by soluble IL-6 receptor alpha mutated in the predicted gp130-binding interface", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 20, 19 May 1995 (1995-05-19), pages 12242 - 12249, XP000566420 *
TAGA ET AL.: "Interleukin-6 receptor and a unique mechanism of its signal transduction", COLD SPRING HARBOR SYMPOSIA ON QUANTITATIVE BIOLOGY, vol. 54, 1989, pages 713 - 722, XP002003860 *
YAWATA ET AL.: "Structure-function analysis of human IL-6 receptor : dissociation of amino acid residues required for IL-6-binding and IL-6 signal transduction through gp130", EMBO J., vol. 12, no. 4, 1993, pages 1705 - 1712, XP002003859 *

Also Published As

Publication number Publication date
ITRM940794A0 (en) 1994-12-06
IT1274350B (en) 1997-07-17
AU4186696A (en) 1996-06-26
JPH09503232A (en) 1997-03-31
EP0742794A1 (en) 1996-11-20
CA2177837A1 (en) 1996-06-07
ITRM940794A1 (en) 1996-06-06
CN1139933A (en) 1997-01-08
WO1996017869A2 (en) 1996-06-13

Similar Documents

Publication Publication Date Title
WO1996017869A3 (en) Interleukin-6 (il-6) antagonists
ALS CNTF Treatment Study Group A double‐blind placebo‐controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis
Maurset et al. Comparison of ketamine and pethidine in experimental and postoperative pain
Chandra et al. Gabapentin versus nortriptyline in post-herpetic neuralgia patients: a randomized, double-blind clinical trial--the GONIP Trial.
CA2305799A1 (en) Composition for the treatment of nicotine addiction containing a nicotine receptor antagonist and an anti-depressant or anti-anxiety drug
NZ305166A (en) 5-substituted-3-(1,2,3,6-tetrahydropyridin-4-yl)- and 3-(piperidin-4-yl)-1h-indoles; preparation and medicaments
HUP0003280A3 (en) Peptides having apolipoprotein a-1 agonist activity, pharmaceutical compositions comprising thereof and their use to treat dyslipidemic disorders
SI0751129T1 (en) Substituted dihydrodibenzo(b,f)azepines, method for their preparation, their use in the treatment of some central nervous system disorders, and pharmaceutical compositions containing them
Seibel et al. Cyclosporine‐induced gingival overgrowth in beagle dogs
HK1027502A1 (en) Composition for treating respiratory and skin diseases, comprising at least one leukotriene antagonist and at least one antihistamine
NZ592039A (en) Combination therapy for the treatment of ocular neovascular disorders
SI0841903T1 (en) Oral pharmaceutical composition containing antimicrobial actives and sustained release pantoprazole
HUP9904362A2 (en) Treatment of upper airway allergic responses with a combination of histamine h1 and h3 receptor antagonists
WO1998008546A3 (en) Therapeutic combinations of rar antagonists and rxr agonists and use thereof
CA2164689A1 (en) NK-1 Receptor Antagonists and 5HT3 Receptor Antagonists for the Treatment of Emesis
HUP0100786A3 (en) Substituted 2-phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them
HUP0302333A3 (en) The use of glatiramer acetate (copolymer 1) for the preparation of pharmaceutical compositions available in the treatment of central nervous system disorders
NZ516477A (en) Therapeutic methods and compositions for the treatment of impaired interpersonal and behavioral disorders
AU2928292A (en) Human il-4 mutant proteins
EP0426055A3 (en) Copolymers from lactic acid and tartaric acid, their preparation and their use
CA2132544A1 (en) Angiotensin ii antagonists against disorders associated with impaired neuronal conduction velocity, especially diabetic neuropathy
WO2000002551A3 (en) Methods and compounds for treating depression
AP2002002501A0 (en) Synergistic combinations of an NK1 receptor antagonist and a gaba structural analog.
AU1583492A (en) Use of sigma receptor antagonists for treatment of amphetamine abuse
WO2000025766A3 (en) Use of nk antagonist for treating gastric asthma

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 95191457.X

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 1995940401

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2177837

Country of ref document: CA

AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA CN JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 1996 687490

Country of ref document: US

Date of ref document: 19961016

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1995940401

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1995940401

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载